

Company name Magenta Medical Ltd. \* Website magentamed.com \* CEO name David Israeli, MD \* CATEGORY: Medical Devices \* (• Why does cardiovascular disease remain the number ONE target for MedTech innovation? \*

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. Magenta is developing a next-generation mechanical circulatory system intended to treat temporary conditions leading to acute cardiac dysfunction, e.g., patients undergoing high-risk percutaneous coronary interventions (HR-PCI) and patients admitted with cardiogenic shock. This \$4B market in the US alone is currently dominated by Abiomed, which was recently acquired by J&J for \$16.6B.

o Core Technology What is the technology, its uniqueness, and its value proposition? At the core of the technology is a self-expanding impeller, allowing the pump to be inserted through any number of commercially available 10Fr sheaths and then expand to 30Fr inside the heart. The pump is the smallest yet the most powerful device in the category.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. The Elevate™ percutaneous LVAD System recently completed an Early Feasibility Study in the US, to be followed by a pivotal study to obtain PMA approval for the first indication (HRPCI). On-going testing will prepare the device for initial human trials for the cardiogenic shock indication.

o Business Strategy Briefly describe how the company will apply its core technology, generate shortterm and long-term revenues. Following PMA approval, the company will commercialize the technology for the HR-PCI indication. Additional clinical studies will expand the approval to cardiogenic shock and other indications. o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans Next will be fundraising to support the US pivotal study, which will begin next year.